西甲硅油(Simethicone) - 在研适应症：腹部膨胀，胃肠胀气_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Imonogas、simeticone、PBK-1701TC

靶点-

作用方式-

作用机制-

治疗领域

其他疾病

在研适应症

腹部膨胀胃肠胀气

非在研适应症

腹痛消化道出血肠易激综合征

原研机构-

在研机构

BERLIN-CHEMIE AGHaleon Australia Pty Ltd.

非在研机构

Abbott Laboratories

McNeil AB

Mayo Clinic

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1952-01-01),

腹部膨胀胃肠胀气

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

73

项与西甲硅油相关的临床试验

NCT06919120

/ Not yet recruiting临床4期IIT

The Study on the Effect of Different Administration Methods of Simethicone in Reducing Bubbles During Bowel Preparation

To find the simplest and most effective method of intestinal preparation for dimethicone administration.

开始日期2025-06-01

申办/合作机构-

NCT06812832

/ Not yet recruiting临床4期

Simethicone as Part of an Enhanced Recovery After Surgery (ERAS) Protocol

By conducting this study, we hope to assess if simethicone (also known as Gas Relief or GasX) has an effect on improving gas pain and bloating specifically in patients undergoing foregut procedures to include bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass), hiatal hernia, and gastric surgery.
The purpose of this research is to gather information on the safety and effectiveness of simethicone. Simethicone (more commonly known as Gas Relief or Gas-X) relieves pressure, bloating, and fullness commonly referred to as gas. It is FDA approved. The use of this medication in this research study is consistent with labeling indications.

开始日期2025-03-01

申办/合作机构

Madigan Army Medical Center

NCT06581783

/ CompletedN/AIIT

Impact of Timing of Premedication on Mucosal Visibility During Endoscopy

UGI endoscopy(esophagogastroduodenoscopy) is the main diagnostic modality for direct visualization ,real time assessment and interpretation of findings encountered. The evaluation of esophagogastroduodenoscopy (EGD) quality measures encompasses several categories, such as structure, procedure, result, and adverse events. The peri-EGD period procedures fall under the procedural area, which is primarily concerned with preventing and minimising missed diagnoses.
. More aid in the identification and characterisation of gastrointestinal mucosal lesions is provided by endoscopes equipped with improved imaging technologies, such as multiband or narrow-band imaging (NBI). Despite these advancements of technological aspects, the unclean mucosal surface of the stomach can make these high-end pieces of equipment virtually useless To visualize properly and diagnose accurately there should be clear visibility of mucus apart from operator experience. Since the stage at diagnosis of upper gastrointestinal cancer is a major factor in survival, early detection is essential in improving the prognosis of patients the main factors responsible for hinderance of mucosal visibility are mucus foam and bubbles, which requires additional care for the clearance to enhance the vision and also decrease endoscopy duration by alleviating the need of repeated flushing and suctioning during endoscopy. The froth and bubbles are made of mucous secretions mixed with gastric juice and bile. Simethicone (polydimethylsiloxane and silicon dioxide) has been proven to be a promising defoaming agent as an endoscopic premedication in removing bubbles . Simethicone works by reducing the surface tension of air bubbles, and releases the trapped air by causing small bubbles to coalesce and collapse . N-acetylcysteine (nac), a mucolytic agent, has also been used as premedication acts by removing the mucous overlying the gastrointestinal mucosa 4-point scale described by Basford et al
1. No adherent mucus and clear views of the mucosa.
2. A thin coating of mucus that did not obscure views of the mucosa.
3. Some mucus/bubbles partially obscuring views of the mucosa (i. E. A small mucosal lesion might be missed without flushing
4. Heavy mucus/bubbles obscuring views of the mucosa (i. E. Extensive flushing is needed to avoid missing small mucosal lesions)

开始日期2024-12-01

申办/合作机构

Asian Institute of Gastroenterology Pvt Ltd.

100 项与西甲硅油相关的临床结果

登录后查看更多信息

100 项与西甲硅油相关的转化医学

登录后查看更多信息

100 项与西甲硅油相关的专利（医药）

登录后查看更多信息

364

项与西甲硅油相关的文献（医药）

2025-04-01·AMERICAN JOURNAL OF GASTROENTEROLOGY

Optimizing Bowel Preparation Quality for Colonoscopy: Consensus Recommendations by the US Multi-Society Task Force on Colorectal Cancer

Review

作者: Jacobson, Brian C. ; Burke, Carol A. ; May, Folasade P. ; Gross, Seth A. ; Robertson, Douglas J. ; Shaukat, Aasma ; Dominitz, Jason A. ; Patel, Swati G. ; Anderson, Joseph C.

This document is an update to the 2014 recommendations for optimizing the adequacy of bowel cleansing for colonoscopy from the US Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. The US Multi-Society Task Force developed consensus statements and key clinical concepts addressing important aspects of bowel preparation for colonoscopy. The majority of consensus statements focus on individuals at average risk for inadequate bowel preparation. However, statements addressing individuals at risk for inadequate bowel preparation quality are also provided. The quality of a bowel preparation is defined as adequate when standard screening or surveillance intervals can be assigned based on the findings of the colonoscopy. We recommend the use of a split-dose bowel preparation regimen and suggest that a 2 L regimen may be sufficient. A same-day regimen is recommended as an acceptable alternative for individuals undergoing afternoon colonoscopy, but we suggest that a same-day regimen is an inferior alternative for individuals undergoing morning colonoscopy. We recommend limiting dietary restrictions to the day before a colonoscopy, relying on either clear liquids or low-fiber/low-residue diets for the early and midday meals. We suggest the adjunctive use of oral simethicone for bowel preparation before colonoscopy. Routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and at the level of the endoscopy unit is also recommended, with a target of >90% for both rates.

2025-04-01·GASTROENTEROLOGY

Optimizing Bowel Preparation Quality for Colonoscopy: Consensus Recommendations by the US Multi-Society Task Force on Colorectal Cancer

Review

作者: Gross, Seth A ; Dominitz, Jason A ; Anderson, Joseph C ; Robertson, Douglas J ; Patel, Swati G ; May, Folasade P ; Jacobson, Brian C ; Shaukat, Aasma ; Burke, Carol A

This document is an update to the 2014 recommendations for optimizing the adequacy of bowel cleansing for colonoscopy from the US Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy. The US Multi-Society Task Force developed consensus statements and key clinical concepts addressing important aspects of bowel preparation for colonoscopy. The majority of consensus statements focus on individuals at average risk for inadequate bowel preparation. However, statements addressing individuals at risk for inadequate bowel preparation quality are also provided. The quality of a bowel preparation is defined as adequate when standard screening or surveillance intervals can be assigned based on the findings of the colonoscopy. We recommend the use of a split-dose bowel preparation regimen and suggest that a 2 L regimen may be sufficient. A same-day regimen is recommended as an acceptable alternative for individuals undergoing afternoon colonoscopy, but we suggest that a same-day regimen is an inferior alternative for individuals undergoing morning colonoscopy. We recommend limiting dietary restrictions to the day before a colonoscopy, relying on either clear liquids or low-fiber/low-residue diets for the early and midday meals. We suggest the adjunctive use of oral simethicone for bowel preparation before colonoscopy. Routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and at the level of the endoscopy unit is also recommended, with a target of >90% for both rates.

2025-04-01·GASTROINTESTINAL ENDOSCOPY

Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer

Review

作者: Gross, Seth A ; Dominitz, Jason A ; Anderson, Joseph C ; Robertson, Douglas J ; Patel, Swati G ; May, Folasade P ; Jacobson, Brian C ; Shaukat, Aasma ; Burke, Carol A

This document is an update to the 2014 recommendations for optimizing the adequacy of bowel cleansing for colonoscopy from the US Multi-Society Task Force on Colorectal Cancer, which represents the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. The US Multi-Society Task Force developed consensus statements and key clinical concepts addressing important aspects of bowel preparation for colonoscopy. The majority of consensus statements focus on individuals at average risk for inadequate bowel preparation. However, statements addressing individuals at risk for inadequate bowel preparation quality are also provided. The quality of a bowel preparation is defined as adequate when standard screening or surveillance intervals can be assigned based on the findings of the colonoscopy. We recommend the use of a split-dose bowel preparation regimen and suggest that a 2 L regimen may be sufficient. A same-day regimen is recommended as an acceptable alternative for individuals undergoing afternoon colonoscopy, but we suggest that a same-day regimen is an inferior alternative for individuals undergoing morning colonoscopy. We recommend limiting dietary restrictions to the day before a colonoscopy, relying on either clear liquids or low-fiber/low-residue diets for the early and midday meals. We suggest the adjunctive use of oral simethicone for bowel preparation before colonoscopy. Routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and at the level of the endoscopy unit is also recommended, with a target of >90% for both rates.

40

项与西甲硅油相关的新闻（医药）

2025-04-17

·北陆药业

北陆药业2024年收入稳健增长净利润同比增幅120%！

近日，北陆药业（300016）发布《2024年年度报告》。2024年度，北陆药业继续稳健经营，实现营业收入98,355.45万元，同比增长10.42%；归属于上市公司股东的净利润1,365.17万元，同比增加119.02%，其中母公司净利润5,635.84万元，同比增加838.39%；归属于上市公司股东的扣除非经常性损益的净利润1,409.44万元，同比增加120.27%。为完成“二次创业”、实现“中国医药制造百强企业”的中长期目标，北陆药业在2024年继续落实“化药+中药”双轮驱动战略布局，主营业务依然专注于对比剂、降糖药以及中枢神经类中成药的生产与销售，同时通过收购承德天原药业进一步扩大中成药战略版图。稳健经营化药板块收入持续增长公司经过近两年的持续改革，逐步克服了化学药主打产品碘对比剂及降糖药管线受集采价格下降带来的巨大挑战，在首次中标执标及后续接续中标工作的推动下，实现了集采产品销量的增长。同时，公司也积极拥抱集采政策，将其作为公司研发、营销等工作的重要考量因素，加大对拟参与集中带量采购产品的研发及申报，力争抓住集采执标的契机，扩大产品的市场份额及品牌影响力。以上举措为公司提供稳定的利润支撑，确保良好的现金流状况，为公司的长期发展奠定坚实的基础。2024年度，公司对比剂产品实现销售收入58,804.95万元，同比增长9.87%，公司降糖类产品实现销售收入12,598.34万元，同比增长33.24%。原料药批文增加持续开拓海外市场原料药是公司化药板块的重要组成部分，北陆药业原料药产品涵盖钆类及碘类的原料药及辅料、中间体等，在保障制剂生产之余，各产品也积极开拓国内及国外市场。控股子公司海昌药业是国内为数不多的具有碘类对比剂原料药生产资质和产能的企业之一，其年产1000吨的碘造影剂项目设有碘海醇、碘克沙醇、碘普罗胺、碘佛醇、碘帕醇、碘比醇及碘美普尔等共计7个品种生产线。除了碘海醇，海昌药业已陆续获批碘克沙醇原料药、碘帕醇原料药等批件，为公司“原料药+制剂”一体化战略进一步夯实基础。同时海昌相关原料药产品也在积极申报海外注册。海昌药业在原料药方面的优势和产业布局的增强，有利于提升公司产品的多样性及公司的综合竞争力。深化中成药战略布局中药收入同比增长19.65%加大中成药板块布局是公司近几年的发展战略之一，公司通过并购中成药企业拓展中成药板块业务，逐步构建丰富的产品矩阵及核心竞争力，努力提升公司的市场份额及影响力，进一步增强公司在中成药领域的品牌形象。九味镇心颗粒是国内第一个通过国家食品药品监督管理总局批准治疗广泛性焦虑症的纯中药制剂，也是公司确立“抗焦虑中药第一品牌”的“黄金单品”。报告期内，公司收购天原药业80%的股权，其拥有的58个中药批文成为公司中成药板块重要组成部分。截至报告期末，天原药业生产、销售的品种共计20种，涵盖清热解毒类、感冒类、补肾强身类、脾胃肠消化类、活血止痛类、肝胆类，其中，核心产品金莲花颗粒系全国独家品种、国家医保乙类、OTC 乙类，系公司全力打造的另一“黄金单品”。公司金莲花颗粒、感冒清热颗粒等中药品种已中标多个地方集采，公司将借助集采执标，协同基层布局，提升金莲花颗粒等产品的市场份额及品牌影响力。报告期内，公司中药制剂实现销售收入16,844.68万元，同比增长19.65%。对比剂全线出海海外收入同比增长15.02%公司海外市场前期的拓展工作成效凸显。公司出口的产品主要为对比剂制剂及原料药，业务覆盖范围为南美洲、非洲、亚洲等市场，公司没有产品出口美国。报告期内，公司对比剂全线产品成功出海并实现营收大幅增长。原料药方面，不仅海昌药业的碘类原料药继续拓展海外市场，沧州分公司生产钆类原料药也逐步实现了国际化。随着欧盟EU GMP认证和巴西ANVISA GMP合规认证的完成，公司对比剂产品的国际化有望进一步提速。九味镇心颗粒在香港和泰国的注册工作继续按计划推进，为出口东南亚等地创造条件。报告期内，公司实现海外营业收入13,216.14万元，同比增长15.02%。储备产品丰富产品梯队建设成型经过2年多的研发投入和收购工作，公司的产品矩阵相对丰富，管线也实现了多元化。报告期内，公司获批钆特酸葡胺制剂及原料药、盐酸帕罗西汀肠溶缓释片、西甲硅油乳剂、复方聚乙二醇电解质散（Ⅲ）、钆布醇注射液新增规格的注册证书，完成了钆喷酸葡胺注射液、钆贝葡胺注射液一致性评价。研发团队不断提升研发效率，为扩大公司在相关领域的战略布局积极储备具有市场竞争潜力的品种。截至目前，公司审评中的项目12项，研发立项项目23项，共计35项。通过并购，公司中药领域批文数量达到59个，其中医保品种45个、基药品种18个、OTC品种41个。九味镇心颗粒、金莲花颗粒、五子衍宗丸、连翘败毒丸、参苓白术丸、消栓通络片、利肝隆片等21个品种在产在销，其余品种皆作为储备品种，等待适当时机开发上市。2025年，公司管理层将在董事会的带领下继续落实各项发展目标。包括但不限于各部门统筹协作，全面落实公司年度目标；加强各生产基地建设及管理，全面提升公司产能；继续推进天原药业的整合与赋能工作，提升中成药业务盈利水平；继续深化营销体系改革，强化营销管理中心职能，狠抓关键政策和重点项目的落地；坚持创新驱动，培养核心团队，提升研发能效；加速公司国际化进程，提升海外市场营收贡献；继续加强内控管理，有效控制风险。关于北陆药业年报更多信息可登录巨潮资讯网www.cninfo.com.cn查询。往期推荐01 【喜报】北陆药业碘海醇注射液欧盟获批上市02北陆药业控股子公司海昌药业碘帕醇化学原料药获批上市03 控股子公司海昌药业碘克沙醇原料药取得韩国注册证书识别二维码关注我们

财报带量采购并购申请上市基因疗法

2025-03-31

·微信

药典委：西甲硅油等3个辅料标准公示！

来源：国家药典委编辑：清风近日，国家药典委发布了3个辅料标准公示，涉及品种为普鲁兰多糖、氢化大豆磷脂酰胆碱和西甲硅油，公示期同为3个月。01 普鲁兰多糖我委拟制定普鲁兰多糖国家药用辅料标准。为确保标准的科学性、合理性和适用性，现将拟制定的标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：陈蕾、朱冉电话：010-67079566、67079581通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：10006102 氢化大豆磷脂酰胆碱我委拟制定氢化大豆磷脂酰胆碱国家药用辅料标准。为确保标准的科学性、合理性和适用性，现将拟制定的标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：陈蕾、朱冉电话：010-67079566、67079581通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：10006103 西甲硅油我委拟制定西甲硅油国家药用辅料标准。为确保标准的科学性、合理性和适用性，现将拟制定的标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：陈蕾、朱冉电话：010-67079566、67079581通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061

2025-03-11

·药事纵横

3月齐聚蓉城 | 安拓思：专业微纳米制剂方案解决商

2025年3月20-21日 2025中国制药工业大会 • 成都站展位号：A39 号 PART 1 演讲预告 3月20-21日在2025中国制药工业大会 • 成都站上，安拓思纳米技术(苏州)有限公司技术总监许春水先生将以“微纳米制剂制备的关键技术工艺流程”这一话题和大家进行交流分享。演讲时间：3月20日 14:40-15:10 演讲地点：会场二药物递送与复杂制剂论坛 PART 2 关于安拓思相比普通制剂而言，复杂制剂是一类更为复杂、先进的载药体系，主要包括脂质体、微球、微晶/纳米晶、胶束等，具有高技术壁垒、高附加值的特点。复杂制剂的制备工艺复杂，关键工艺步骤较多，工艺参数的变化对成品的质量影响非常大，需要精准控制药物的粒度及粒度分布，因此选择正确的制药设备也是决定其成功的关键环节。公司简介安拓思纳米技术（苏州）有限公司成立于2001年，隶属于上海多宁集团，是一家专业从事细胞工程、医药、精细化工、新能源材料、食品化妆品等纳米制备设备与工艺辅助，集技术研发、生产、销售于一体的苏州高新技术企业。公司建有先进标准化车间及复杂制剂纳米化设备研究中心，提供从实验型到大型生产不同阶段需求的设备及技术解决方案。公司主营高压均质机、微射流均质机、微流控、脂质体挤出仪等设备和技术服务，致力于成为纳米均质服务领域的专家并竭诚为客户提供优质的服务与解决方案。高压均质机微射流均质机微流控脂质体挤出器关于安拓案例分析环孢素滴眼液西甲硅油棕榈酸帕利哌酮无菌混悬液 /D10D50D90Span原研0.4880.971.711.29球磨0.481.213.11ATS0.4790.991.81.3 泊沙康唑口服混悬液客户现场无菌吸入剂生产线 2000L连续乳化系统脂质体生产线联系方式 Amanda 13306586060 码上免费报名 2025年3月20-21日 • 成都

财报

100 项与西甲硅油相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
腹部膨胀	美国	-	1952-01-01
胃肠胀气	美国	-	1952-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹痛	临床3期	俄罗斯	Abbott Laboratories	2020-11-27
肠易激综合征	临床3期	俄罗斯	Abbott Laboratories	2020-11-27
消化道出血	临床1期	美国	Mayo Clinic	2010-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05951712 (Pubmed \| Indian J Gastroenterol)	N/A	-	800	simethicone (Water)	繭製遞觸構鏇範衊艱憲(鹹簾願願鏇遞繭鹹簾製) = 廠製淵鬱積淵觸願鏇餘醖艱醖構積淵膚淵齋襯 (膚觸窪鏇鏇糧蓋窪網蓋, 9 ~ 13)	积极	2024-10-01
				Simethicone	繭製遞觸構鏇範衊艱憲(鹹簾願願鏇遞繭鹹簾製) = 餘網顧遞積網齋顧遞糧醖艱醖構積淵膚淵齋襯 (膚觸窪鏇鏇糧蓋窪網蓋, 6 ~ 8)
NCT05175131 (CTgov)	临床3期	腹痛 \| 肠易激综合征	465	Simethicone+Mebeverine (Mebeverine+Simethicone Combination)	齋餘齋夢積壓遞壓餘願(夢膚蓋簾衊糧夢築蓋膚) = 鹹範網觸餘憲觸範鹽夢艱製選廠廠窪窪築餘餘 (夢願製憲衊選蓋鏇積憲, 3.42) 更多	-	2024-01-03
				Mebeverine (Mebeverine)	齋餘齋夢積壓遞壓餘願(夢膚蓋簾衊糧夢築蓋膚) = 衊衊壓積構顧範網鬱蓋艱製選廠廠窪窪築餘餘 (夢願製憲衊選蓋鏇積憲, 3.48) 更多
UEGW2023	N/A	-	-	40mg simethicone 20-30 minutes prior to procedure	醖夢遞窪積鑰衊製鹽蓋(糧鹹壓廠鑰壓餘膚鬱鹹) = 夢顧廠選築襯鹹糧憲選淵築齋餘顧憲網夢繭鏇 (膚築衊襯膚網構蓋製廠 )	-	2023-10-15
				40mg simethicone 0-10 minutes prior to procedure	醖夢遞窪積鑰衊製鹽蓋(糧鹹壓廠鑰壓餘膚鬱鹹) = 膚鬱鬱衊築遞製鏇醖鬱淵築齋餘顧憲網夢繭鏇 (膚築衊襯膚網構蓋製廠 )
PREMEDICATION WITH SIMETHICONE (UEGW2021)	N/A	-	110	Simethicone 200mg	襯選積積壓選窪網鹽遞(膚糧夢膚製鬱獵憲窪願) = 淵壓鏇簾夢蓋齋簾艱醖醖選餘淵淵衊窪壓憲鏇 (選膚醖糧遞遞壓憲醖淵 ) 更多	积极	2021-10-02
				Placebo	襯選積積壓選窪網鹽遞(膚糧夢膚製鬱獵憲窪願) = 簾膚蓋憲襯齋膚鬱鹹鏇醖選餘淵淵衊窪壓憲鏇 (選膚醖糧遞遞壓憲醖淵 ) 更多
NCT03119168 (Pubmed \| Gastrointest Endosc)	临床4期	-	268	Polyethylene glycol plus SIM	遞憲顧繭淵範範積鏇憲(糧鹽構遞廠構餘襯糧憲) = 獵壓積衊蓋鏇獵壓鹹蓋製構鏇鏇鏇淵鑰膚網壓 (膚膚網鏇齋膚窪鹽餘獵 ) 更多	-	2019-07-01
				Polyethylene glycol	遞憲顧繭淵範範積鏇憲(糧鹽構遞廠構餘襯糧憲) = 遞衊簾廠醖衊構製製獵製構鏇鏇鏇淵鑰膚網壓 (膚膚網鏇齋膚窪鹽餘獵 ) 更多
NCT03119168 (CTgov)	临床4期	腺瘤	268	Simethicone Solution (Simethicone Solution + Polyethylenglycol)	構憲網製鏇鏇醖膚鑰窪 = 膚餘鹹遞糧願糧網製艱窪糧鏇壓窪淵憲觸襯淵 (鑰願簾夢製壓鹹齋鑰範, 選遞構艱衊範鹹築積範 ~ 鬱廠淵壓艱築積範糧淵) 更多	-	2019-06-05
				Polyethylenglycol (Polyethylenglycol)	構憲網製鏇鏇醖膚鑰窪 = 廠憲艱廠膚憲夢積膚願窪糧鏇壓窪淵憲觸襯淵 (鑰願簾夢製壓鹹齋鑰範, 製鹽選範壓衊積築鹽簾 ~ 獵艱糧網觸膚壓獵遞願) 更多
NCT02217982 (IIT9, CTgov)	临床4期	复发-缓解型多发性硬化	5	DMF (Control Group)	鏇觸築夢艱蓋顧遞蓋醖(網鹹積壓襯膚積願築範) = 夢網鏇製願淵夢網選網廠廠夢衊廠構獵製願蓋 (醖鑰獵糧遞糧廠積選膚, 糧願淵衊糧壓衊獵壓鏇 ~ 構齋襯齋糧簾選鑰築製) 更多	-	2017-01-06
				Peanut Butter+Simethicone+Loperamide (Treatment Arm)	鏇觸築夢艱蓋顧遞蓋醖(網鹹積壓襯膚積願築範) = 築鑰顧壓網遞顧壓構衊廠廠夢衊廠構獵製願蓋 (醖鑰獵糧遞糧廠積選膚, 醖糧醖範選繭鹹壓鑰廠 ~ 遞鏇鹹衊蓋鹽衊築壓壓) 更多
NCT01312038 (CTgov)	临床2期	功能障碍 \| 中耳炎	25	Placebo (Placebo)	鹹衊鹽鏇製顧膚製廠顧(願襯鬱製觸獵築觸願襯) = 鹹遞構網鹽壓衊顧夢蓋繭繭觸構簾觸艱衊夢蓋 (遞蓋蓋遞構醖窪範餘齋, 0.34) 更多	-	2016-06-27
				Simethicone (Simethicone)	願觸齋膚夢鏇壓範製蓋(憲鹹製鹹遞窪鑰壓網鑰) = 餘顧餘糧餘艱鏇積選醖齋醖襯廠製襯襯廠窪選 (範蓋鏇製積鏇顧獵糧鑰, 積窪衊範構廠鬱齋顧製 ~ 壓觸鑰網艱鹹齋製遞壓) 更多
NCT02555228 (CTgov)	临床2/3期	胃腺瘤	54	Simethicone (Simethicone Premedication)	齋鏇鑰夢憲繭構糧積構(醖構繭製窪夢淵夢餘膚) = 鑰糧襯製繭膚遞獵衊選網鬱醖憲衊淵構膚淵廠 (蓋壓遞繭憲鑰鑰願鹹選, 1.65) 更多	-	2016-03-15
				Water (Placebo)	齋鏇鑰夢憲繭構糧積構(醖構繭製窪夢淵夢餘膚) = 醖廠製壓壓鏇簾顧願鏇網鬱醖憲衊淵構膚淵廠 (蓋壓遞繭憲鑰鑰願鹹選, 1.97) 更多
UEGW2015	N/A	-	-	PEG-Asc	獵鬱醖窪鹹繭鏇觸鹽鏇(簾壓艱構艱淵積範選鏇) = PEG-Asc with simethicone caused fewer gastrointestinal symptoms (ex. abdominal fullness, colicky pain, general discomfort) than PEG-Asc 簾膚蓋顧鑰窪淵廠糧艱 (憲繭選鬱製積製鏇網夢 )	-	2015-10-01
				PEG-Asc with simethicone